Revolutions Medical (OTCMKTS:RMCP) & PROCEPT BioRobotics (NASDAQ:PRCT) Financial Review

Revolutions Medical (OTCMKTS:RMCP) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Institutional & Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 10.5% of Revolutions Medical shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Revolutions Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolutions Medical	N/A	N/A	N/A
PROCEPT BioRobotics	-58.73%	-37.85%	-26.20%

Earnings and Valuation

This table compares Revolutions Medical and PROCEPT BioRobotics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolutions Medical	N/A	N/A	N/A	N/A	N/A
PROCEPT BioRobotics	$176.58 million	21.64	-$105.90 million	($2.12)	-35.05

Revolutions Medical has higher earnings, but lower revenue than PROCEPT BioRobotics.

Volatility & Risk

Revolutions Medical has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Revolutions Medical and PROCEPT BioRobotics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolutions Medical	0	0	0	0	N/A
PROCEPT BioRobotics	0	0	7	0	3.00

PROCEPT BioRobotics has a consensus target price of $78.17, suggesting a potential upside of 5.19%. Given PROCEPT BioRobotics’ higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Revolutions Medical.

Summary

PROCEPT BioRobotics beats Revolutions Medical on 6 of the 9 factors compared between the two stocks.

About Revolutions Medical

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.